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Abstract
Background: The spontaneously hypertensive rat (SHR) has been used to model changes in the central nervous
system associated with cognitive-related disorders. Recent human and animal studies indicate a possible relationship
between cognitive deficits, insulin resistance and hypertension. We aimed to investigate whether cognitively impaired
SHRs develop central and/or peripheral insulin resistance and how their cognitive performance is influenced by
the animal’s sex and age as well as strains used for comparison (Wistar and Wistar-Kyoto/WKY).
Methods: Three and seven-month-old SHR, Wistar, and WKY rats were studied for their cognitive performance
using Morris Water Maze (MWM) and Passive Avoidance tests (PAT). Plasma glucose and insulin were obtained
after oral glucose tolerance tests. Cerebral cortex, hippocampus, and striatum status of insulin-receptor (IR) β-subunit
and glycogen synthase kinase-3β (GSK3β) and their phosphorylated forms were obtained via ELISA.
Results: SHRs performed poorly in MWM and PAT in comparison to both control strains but more pronouncedly
compared to WKY. Females performed poorer than males and 7-month-old SHRs had poorer MWM performance than
3-month-old ones. Although plasma glucose levels remained unchanged, plasma insulin levels were significantly
increased in the glucose tolerance test in 7-month-old SHRs. SHRs demonstrated reduced expression and increased
activity of IRβ-subunit in cerebral cortex, hippocampus, and striatum with different regional changes in phospho/total
GSK3β ratio, as compared to WKYs.
Conclusion: Results indicate that cognitive deficits in SHRs are accompanied by both central and peripheral insulin
dysfunction, thus allowing for the speculation that SHRs might additionally be considered as a model of insulin
resistance-induced type of dementia.
Keywords: Age, Control strain, Gender, Glycogen synthase-kinase 3β, Insulin resistance, Learning and memory,
Spontaneously hypertensive rat
Background
The spontaneously hypertensive rat (SHR) was inbred
from the Wistar-Kyoto rat strain (WKY) [1]. SHRs were
initially developed as a model for hypertension but were
eventually shown to develop pathologies at the meta-
bolic, behavioral, and cognitive level. The metabolic
pathology is manifested as systemic insulin resistance
[2]; the behavioral symptoms resemble attention-deficit
hyperactivity disorder (ADHD) (hyperactivity, impulsiv-
ity, impaired ability to withhold responses, and poorly
sustained attention) [3–5]; and the cognitive pathology
is manifested as learning and memory deficits [6–8].
Several studies have explored the link between an insulin
resistant brain state and cognitive impairment, particu-
larly in dementia of the Alzheimer type as reviewed else-
where [9–11]. Insulin and insulin receptors (IR) in the
brain have been shown to regulate glucose metabolism
[12], as expected, but IR also triggers complex signaling
pathways in the brain [13–17]. These pathways involve
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glycogen synthase-kinase-3 (GSK3) inhibition, via protein
kinase B (Akt/PKB) [16, 17]. In addition, IR influences the
accumulation/degradation of amyloid-β and tau protein,
the major neuropathological hallmarks of the memory loss
developed in Alzheimer’s disease (AD) [13–15]. We aimed
to investigate whether cognitively impaired SHRs develop
a central insulin resistance in parallel to the peripheral
one, but data published so far on cognitive performance in
the SHR model have indicated that measurements were
done using different cognitive tests, comparing different
control strains, using animals of different ages and not al-
ways done using both sexes [3, 18–32]. Since these factors
might interfere with cognitive performance in rats, we
have additionally explored their possible influence on
learning and memory functions in the SHR model.
In brief, following the comparison between different
control strains and sexes which showed that female
SHRs demonstrate more pronounced cognitive deficits
than males, particularly in comparison to the WKY con-
trols, our studies showed that cognitive deficits in female
SHRs are accompanied by peripheral and central insulin
resistance in 7- but not in 3-month old animals in com-
parison to WKY controls.
Methods
Animals
The experiments were performed on Wistar SHR and 2
normotensive control strains, Wistar-Kyoto (WKY) and
Wistar rats, all purchased from Charles River Laborator-
ies (Kisslegg, Germany). Animals were acclimated for
2 weeks before cognitive testing which was performed at
the Department of Pharmacology, University of Zagreb
School of Medicine (Zagreb, Croatia). Animals con-
sumed standardized food pellets and water ad libitum.
Ethics
All procedures were performed under the guidance of
the Principles of Laboratory Animal Care (NIH Publi-
cation No. 80-23, revised in 1996) and in accordance
with the European Communities Council Directive of
24 November 1986 (86/609/EEC) and the Croatian Act
on Animal Welfare (NN 135/2006). All experiments
were approved by the University of Zagreb School of
Medicine (Licence No.04-1343-2006).
Experimental design
Three different experiments were performed in vivo to
explore the effect of (1) control rat strain, with 12-week
male SHR, WKY and Wistar rats, (2) sex, with 12-week-
old female and male SHR and WKY rats, and (3) age,
with 12- and 28-week-old (i.e. 3- and 7-month-old) female
SHR and WKY rats. Animal age in the third experiment
corresponded to young adult and older, “middle-aged”
humans [33] as well as represented the periods of rising
blood pressure (3 months) and sustained/chronic hyper-
tension (7 months) [34, 35]. There were 10 animals per
group in all experiments.
Cognitive testing
Morris Water Maze (MWM) swimming test
The MWM tested learning ability and spatial memory as
previously described and used in our experiments [36, 37]
(details provided in the Additional file 1). The time needed
to find the platform (seconds) and the number of errors
(incorrect entries into quadrants with no platform) were
recorded in training trials during 4 consecutive days while
the time spent searching for the platform after entering
quadrant IV and number of errors were recorded in the
probe trial that followed.
Passive Avoidance test (PAT)
The step-through PAT was performed two days after
finishing the MWM test and exploited a fear-motivated
tendency of a rat to escape from an illuminated area
into a dark area as previously described and used in
our experiments [36, 37]. Latency time (seconds) before
entering the dark area was recorded on the third testing
day. A more detailed PAT method is provided in the
Additional file 1.
Oral glucose tolerance test
The OGTT was performed after the rats were under
deep chloral hydrate (300 mg/kg i.p.) anesthesia, in ac-
cordance with the ethical requirements for laboratory
animal procedures of the Medical School University of
Zagreb. Blood samples were sequentially collected from
the tail vein (50 μL; between 8 and 12 a.m.) for plasma
glucose measurements at baseline, 30, and 60 min after
the challenge. The post-OGTT cut-off time of 60 min
corresponded to the duration of anesthesia from a single
chloral hydrate dose. Animals were sacrificed after the
last blood withdrawal still in deep anesthesia, 2 days
after last cognitive testing.
Preparation of brain regions
Macrodissection of three brain regions (frontal cortex,
striatum, and hippocampus) was performed on a cold
plate (4 °C) by a standard procedure and according to
the rat brain atlas [38]. The brain samples were snap frozen
and stored at -80 °C until further analysis.
Brain homogenates
Frozen brain tissue from each rat was weighed, and a
4-fold concentration of RIPA buffer (Sigma-Aldrich,
Schelldorf, Germany) was added with protease and phos-
phatase inhibitors (Sigma-Aldrich, Schelldorf, Germany).
Samples were homogenized via ultrasonic disruption
(15 % amplitude, 10 s) at 4 °C. After homogenization, the
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probes were centrifuged at 44,000 × g at 4 °C for 10 min.
Clear supernatant (which contained proteins) was collected
into a fresh tube for further analysis.
Protein concentration
For each sample, protein concentrations were evaluated
with the standard Bradford method for protein measure-
ment [39].
Biochemistry
Plasma glucose concentrations were measured with a com-
mercial kit (Glucose-PAP Test, Herbos Diagnostics) and
the glucose oxidase method. Plasma insulin levels were
assessed with a commercial kit for an Enzyme-Linked Im-
munosorbent Assay (ELISA; Crystal Chem Inc, IL, USA;
Cat. No. 90060), which was more sensitive for quantitative
analysis (sensitivity <0.8 units/ml) than a Western Blot
assay. ELISAs were used to evaluate brain expression levels
of the insulin receptor (IR) β-subunit (total), the two forms
of the phosphorylated-IRβ subunit, pTyr1162/1163 and
pTyr1158 (Calbiochem, Darmstadt, Germany; CBA039,
CBA038, and Invitrogen GmbH, Darmstadt, Germany;
KHR9121, respectively), the glycogen synthase-kinase
(GSK)-3 β-subunit (total), and the phosphorylated form
of GSK-3β, pSer9 (Calbiochem, Darmstadt, Germany;
CBA068 and CBA069, respectively). All ELISAs were
performed as recommended by the manufacturer. In the
ELISA tests, brain homogenates were run in parallel with
standards for concentration evaluations.
Statistical analysis
The statistical analyses of all data were performed with
StatView for Windows (SAS Institute Inc., Cary, NC,
USA; Version 9.3). Data from the MWM training trials
were analyzed by fitting general(ized) linear mixed models
(Poisson link for the number of errors, normal for escape
latency. Instead of adjustment for multiple comparisons,
which we considered too conservative, main effects (across
all days or both genders/strains) of strain and gender are
given with 95 % confidence interval (CI); contrasts arising
from interactions with up to 4 cross-products (strain*gen-
der across all days, strain*age across all days) are given
with 97.5 % CI; contrasts arising from strain*(sex or age)*-
day interaction are given with 99 % CI (the significance
level p < 0.05, <0.025 or <0.01, respectively). Additionally,
the multifactorial analysis of variance (MANOVA),
followed by the analysis of Post-Hoc Scheffé test, and the
Mann–Whitney U-test, was used. The significance level
was set to p <0.05.
Results
Cognitive deficits
After demonstrating that SHR rats performed poorly in
MWM training trials regardless of the control strain
(WKY or Wistar) (p < 0.05), but that the difference was
more pronounced compared to WKY (p < 0.05), WKY
rats were used as a control in further experiments,
which consistently showed that SHRs performed worse
regardless of sex (p < 0.05) or age (p < 0.05), as pre-
sented in Additional file 2: Figure S2 & Additional file 3:
Figure S3.
As we could show that the most pronounce differ-
ences in cognitive deficits in training trials were in fe-
male SHR compared to female WKY (p < 0.05), and in
some extent due to age (p < 0.05) (Additional file 3:
Figure S3), the cognitive performance of 3- and 7-
month old female SHR and WKY rats was further re-
corded in the MWM probe trials. Both SHR age
groups demonstrated significant deficits in spatial
memory; they spent less time swimming in the quadrant
from which the platform has been removed (p < 0.0001;
Fig. 1a) and made more errors than controls (7-month-old
SHRs, p < 0.05; 3-month-old SHRs, p = 0.06; Fig. 1b).
Female SHRs of both ages also showed marked deficits
in fear-motivated memory in the PAT. They demon-
strated much lower post-shock latency times than
WKY controls (p < 0.0001, Fig. 1c), with no age-related
effect being detected.
Insulin receptor signaling in the brain
Based on the results of cognitive testing, female SHRs
were further used to investigate whether cognitive deficits
are accompanied by alterations of insulin signaling in the
brain, when compared to WKYcontrols.
Brain IRβ expression levels
SHRs had, in general, lower total IRβ subunit levels
than WKY rats in all brain regions, particularly in the
hippocampus and striatum (Fig. 2a) but showed age-
dependent increment in IRβ level in the frontal cortex
only (p < 0.05, Fig. 2a) in contrast to region-dependent
variability in the total IRβ levels with aging in WKY
controls (frontal cortex–increased /p < 0.05/, hippo-
campus–decreased /p < 0.05/, striatum–unchanged, in
7- compared to 3-month-old animals, respectively)
(Fig. 2a).
Brain IR activity
IR activity expressed as the ratio of phosphorylated IR
(pTyr1162/1163 and pTyr1158) to total IRβ (higher ratio in-
dicating higher IR activity) was significantly increased in
all investigated brain regions in 7- compared to the 3-
month-old animals in both SHRs and WKYs but the
magnitude of age-dependent increment was larger in
SHRs than in WKYs (Fig. 2b). Compared to WKYs,
SHRs had significantly higher IR activity at both ages in
the hippocampus and striatum and at 7-month of age in
the frontal cortex (p < 0.05; Fig. 2b).
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Brain GSK3β expression levels and activity
Total GSK3β level in the frontal cortex (p < 0.0005),
hippocampus (p < 0.0001) and striatum (p < 0.005) was
significantly lower in 3- compared to 7-month-old SHRs
(Fig. 3a) while WKYs expressed such age-dependent dif-
ference only in the hippocampus (p < 0.05; Fig. 3a). Since
GSK3β activity is regulated mainly via phosphorylation
of the serine-9 residue, we determined its relative
activity expressed as the ratio of the phosphorylated
(inactive) to total GSK3β form (low ratio indirectly sug-
gests high GSK3β activity). Age-dependent tendency of
decrement in this ratio (increased GSK3β activity) was
observed in both SHRs and WKYs with significance
reached only in 7-month-old animals but with some re-
gional specificity; SHRs - frontal cortex and striatum
(p < 0.05), WKY - frontal cortex (p < 0.005) and hippo-
campus (p < 0.0001) (Fig. 3b).
Plasma glucose and insulin levels
Both 3- and 7-month-old SHRs showed a significant in-
crease in plasma glucose after 30 and 60 min compared
to the baseline levels in the oral glucose tolerance test
(OGTT; Fig. 4a and b). A similar time-pattern effect was
detected in WKYs with the exception of the 60 min
time-point in 7-month-old WKYs when glucose levels
were not significantly different from the respective base-
line values (Fig. 4a and b). In contrast, the time-course
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of the plasma insulin levels showed opposite effects in
the 3- and 7-month-old rats. In 3-month-old animals,
SHRs showed only modest increase in plasma insulin
with borderline significant differences at 60 min com-
pared to the baseline levels, while insulin plasma levels
in WKYs were significantly increased at both time-
points compared to their baseline level (Fig. 4c). In the
7-month-old animals, both the SHRs and WKYs showed
significant increases in plasma insulin at the 60 min
time-point only, compared to their baseline levels
(Fig. 4d). Analysis of the area under the curve (AUC)
values of plasma glucose and insulin (Fig. 4e-f ) in SHRs
and WKYs of both ages pointed to an age-dependent
disruption of glucose metabolism for both groups. But
to the contrary, plasma insulin AUC was significantly
increased with age in the SHR animals, while no signifi-
cant age-dependent difference was observed in WKY
controls.
Discussion
Consistent with previous reports [7, 40–42], this study
confirmed that the SHR model develops significant
memory and learning deficits, which was a prerequisite
for the study’s main aim: to explore whether cognitive
deficits in SHRs are accompanied by peripheral/central
metabolic abnormalities. Considering literature data dis-
cussing that selection of corresponding control group
(rat strain and usage of inbred, e.g. Wistar-Kyoto/WKY/,
or outbred, e.g. Wistar, Sprague–Dawley/SD/animals) as
well as age and sex might affect the results of cognitive
testing [23, 25, 43], we investigated the cognitive profiles
of the optimal control strain and SHR gender and identi-
fied those which demonstrated most pronounced differ-
ence between the control and SHR group, to be used in
exploring the metabolic changes in this model.
Our experiments (Additional file 2: Figure S2 &
Additional file 3: Figure S3) provided evidence that the
SHR model performed poorly compared to control re-
gardless sex, but females performed worse than males.
Some literature data have suggested that hyperactivity be-
havior might influence the cognitive performance of SHRs
and that locomotor activity (distraction) could be a con-
founding factor in spatial memory tasks [24], for example,
in hyperactive female SHRs [32]. Although increased loco-
motor activity might act as a distraction in achieving a
goal, hyperactivity in a cognitively normal rat might also
lead to acheiving this goal in a more focused, direct
way than in a rat with normal locomotor activity (which
was not the case in our experiments). The present data
(Additional file 2: Figure S2), however, strongly suggest
that the observed deficit manifested as an increased num-
ber of errors was not due to hyperactivity: compared to
controls, SHR rats made more errors (Additional file 2:
Figure S2a, d) and had longer latency times (Additional
file 2: Figure S2b, e), but time spent per one error was the
same in all strains (Additional file 2: Figure S2c), and with
adjustment for the number of errors, latency times did not
differ between the SHR and control strains (Additional
file 2: Figure S2F). Had hyperactivity (as a distraction
factor) been the cause of the increased error rate, one
would have expected to see reduced latency times per
one error (e.g., faster swimming due to locomotor
hyperactivity), or extended latency times per error (e.g.,
“non-focused” swimming due to hyperactivity), but not
the same latency time per error. Since cognitive deficits in
our experiments with cognitively more impaired female
SHRs were more pronounced in comparison to WKY than
to Wistar animals, female SHRs and WKYs were used for
further exploration of metabolic abnormalities. WKY and
Wistar strains have been frequently used as a control for
memory testing in SHRs [22, 23, 25, 43, 44], but usually
not in the same experiment with the exemption of the
work of Gattu et al. [45, 46] which showed cognitive
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impairment of 1- and 3-month-old male SHRs compared
to both these control strains.
A growing body of evidence points to the association
of cognitive deficits and insulin resistance in humans
and in animals [47–49], an issue that has been poorly
explored in the SHR model; a presence of systemic insu-
lin resistance in SHRs has been manifested by a plasma
insulin response in 7 week-old animals (sex not speci-
fied) [2], and indirectly by a reduced insulin-stimulated
glucose transporter bioavailability in adipocytes [50],
while an unchanged expression of insulin receptor in the
brain of 3-month-old male SHRs was reported by Yang
et al. [51]. Our results indicate that the plasma insulin
response to an oral glucose challenge is altered in SHRs
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compared to WKY but that the direction of change de-
pends on a respective time-point of its measurement;
lower plasma insulin response in 3-month (AUC = 25/
SHR vs. 60/WKY) and greater in 7-month-old female
SHRs (AUC = 58/SHR vs. 45/WKY) despite the similar-
ity in the total serum glucose response in SHRs and
WKYs. Such a difference in insulin AUC after OGTT
was not detected in a recent study investigating various
combinations of metabolic syndrome and AD markers
in male SHR animals [51], indicating that a possible gen-
der influence in this model might play a role not only in
cognition but also in insulin response. Additionally, it
could not be excluded that this time-dependent insulin
response might correlate with an observed tendency for
age-dependent worsening of learning and memory func-
tions in female SHRs, indirectly also reflecting a difference
in metabolic response between early (3-month-old) and
chronic (7-month-old) hypertension.
Although several studies have suggested that learning
and memory deficits observed in SHR animals were in-
dependent of hypertension [30, 40, 52], others did find
correlations between hypertension and cognitive deficits
[5, 6, 41, 53]. Having in mind that aging, female gender,
and hypertension are considered risk factors for demen-
tia, particularly of the Alzheimer’s type (see meta-
analysis in www.alzrisk.org and [54–57], usage of aged
SHR animals with reduced cognitive performance might
be worth considering as a possible model of a certain
type of dementia [5, 58].
Several findings in SHR animals point to their suscepti-
bility to metabolic alterations in the brain. For example,
recent findings of Ritz et al. [59] showed that gene expres-
sion alterations in the cortex of 2-month-old (pre-hyper-
tension) and 9-month-old SHRs (compared to WKY)
pointed to a vulnerability to high-energy requirements in
these animal models. Furthermore, studies of cerebral glu-
cose utilization in SHR compared to WKY were found to
be lower at aged animals (around 6 months) [60, 61] while
not different in younger ones (12 weeks only) [62, 63].
Gene expression profiling in cell cultures originating from
the brain stems of SHR and WKY animals revealed signifi-
cantly enriched genes belonging to molecular pathways of
the ATPase activity [64], further supporting the involve-
ment of energy metabolism dysfunction in this model.
Glucose/energy hypometabolism in the brain might be a
consequence of an insulin resistant brain state [65, 66],
which seems to be involved in cognitive decline, as
suggested in particular in AD and its animal models
[9–11, 47, 67]. This hypothesis has been recently discussed
for AD patients pointing to the pathophysiological import-
ance of the vicious cycle of glucose/energy demand, vascu-
lar cognitive impairment, dementia, and aging, suggesting
that an understanding of how vascular and metabolic
factors interfere with a progressive loss of functional
neuronal networks becomes essential for developing ef-
ficient drugs to prevent cognitive decline in the elderly
[68]. Keeping in mind that glucose metabolism in the
brain is under control of brain IR [12], our findings of
dysfunction in brain IR and its downstream signaling
cascade might contribute to the pathophysiological
mechanisms of the cerebral glucose hypometabolism in
SHRs reported in the literature [60]. We generally
found lower total levels of the IRβ subunit in SHRs
compared to WKYs in all brain regions investigated, re-
gardless of a rat’s age. This finding might indicate that
SHRs have a general deficit in brain insulin signaling
pathways. Furthermore, we observed an increased IR
activity in the 7-month-old SHRs, measured as the ra-
tio of phosphorylated to total IRβ subunits, which
might represent a compensatory mechanism covering
for reduced IRβ level. Yang and colleagues [51] could
not find difference in IR, which, however, was mea-
sured in the whole brain (and not in specific brain re-
gions as in our experiment) of young male SHR
animals compared to WKY. Our findings demonstrated
that GSK3β activity (indirectly measured by p/total
GSK3β ratio), which is down-stream to IR signaling
and is linked to hyperphosphorylation of tau-protein
[69], increased with aging in the cerebral cortex of both
the SHR and WKY group, while in the hippocampus it
was significantly increased only in 7-month-old female
SHRs compared to corresponding WKYs. In recent
years, the over-activation of GSK3β in the brain has
been reported to be involved in the pathophysiology of
AD and of type-2 diabetes mellitus [70].
These results further support the hypothesis that the
SHR model develops insulin resistance in the brain,
manifested both at the level of IR protein/activity and its
downstream signaling pathway, as well at the periphery.
Moreover, our results obtained in the same pool of ani-
mals demonstrate for the first time the co-existence of
hypertension with peripheral and central insulin resist-
ance and cognitive deficits in SHR model.
Conclusions
This study provides the first combined evidence that cog-
nitive deficits in the SHR model are accompanied by
insulin-signaling dysfunction in the brain in parallel to the
existence of peripheral insulin resistance. Factors like rat
strain used for comparison, SHRs age and/or hypertension
duration as well as sex should be considered in the inter-
pretation of cognitive and metabolic performance of the
SHR model. Further studies are required to address the
question of a possible causal relationship between these
metabolic and cognitive impairments in SHRs and accord-
ingly explore whether SHRs might be also considered as a
model of insulin resistance-induced type of dementia, in
addition to being a model of hypertension and ADHD.
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